Skip to main content
Top
Published in: Annals of Surgical Oncology 6/2014

01-06-2014 | Endocrine Tumors

Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer

Authors: K. M. Schulte, MD, FRCS, N. Talat, BSc (Hons), G. Galata, MD, J. Gilbert, PhD, J. Miell, FRCPE, FRCP, L. C. Hofbauer, MD, A. Barthel, MD, S. Diaz-Cano, MD, PhD, FRCPath, S. R. Bornstein, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2014

Login to get access

Abstract

Background

Parathyroid cancer has a poor mid-term prognosis, often because of local recurrence, observed in half of all patients. Modern diagnostic workup increasingly enables a preoperative diagnosis of parathyroid cancer. There is limited evidence that more comprehensive oncologic surgery can reduce the risk of local recurrence. This study aims to identify the best specific surgical approach in parathyroid cancer.

Methods

This observational cohort study comprises 19 consecutive patients who had undergone oncologic or nononcologic resection for parathyroid cancer. Baseline parameters were compared by using univariate analysis; outcomes were assessed by χ 2 testing and Kaplan–Meier statistics.

Results

Fifteen of 19 patients were primarily operated on in our tertiary center between 1996 and 2013, and four were referred for follow-up because of their cancer diagnosis. Patient cohorts defined by histologic R-status were comparable for established risk factors: sex, calcium levels, low-risk/high-risk status, and presence of vascular invasion. Oncologic resections were performed in 13 of 15 patients primarily treated in the center and 0 of 4 treated elsewhere (χ 2 = 5.6; p < 0.01). R0 margins were achieved in 11 of 13 (85 %) undergoing oncologic resection and 1 of 6 (17 %) undergoing local excision (χ 2 = 8.1; p < 0.01). R0 margins and primary oncologic resection were associated with higher disease-free survival rates (χ 2 = 7.9; p = 0.005 and χ 2 = 4.7; p = 0.03, respectively). Revision surgery achieved R0 margins in only 2 of 4 (50 %) of patients.

Conclusions

In parathyroid cancer, a more comprehensive surgery (primary oncologic resection) provides significantly better outcomes than local excision as a result of reduction of R1 margins and locoregional recurrence.
Appendix
Available only for authorised users
Literature
1.
go back to reference Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–44.PubMedCrossRef Obara T, Fujimoto Y. Diagnosis and treatment of patients with parathyroid carcinoma: an update and review. World J Surg. 1991;15:738–44.PubMedCrossRef
2.
go back to reference Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRef Ruda JM, Hollenbeak CS, Stack BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism from 1995 to 2003. Otolaryngol Head Neck Surg. 2005;132:359–72.PubMedCrossRef
3.
go back to reference Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538–44.PubMedCrossRef Hundahl SA, Fleming ID, Fremgen AM, Menck HR. Two hundred eighty-six cases of parathyroid carcinoma treated in the US between 1985–1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538–44.PubMedCrossRef
4.
go back to reference Talat N, Schulte K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.PubMedCrossRef Talat N, Schulte K. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.PubMedCrossRef
5.
go back to reference Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.PubMedCrossRef Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.PubMedCrossRef
6.
go back to reference Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8:612–22.PubMedCrossRef Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8:612–22.PubMedCrossRef
7.
go back to reference Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–73.PubMedCrossRef Sidhu PS, Talat N, Patel P, et al. Ultrasound features of malignancy in the preoperative diagnosis of parathyroid cancer: a retrospective analysis of parathyroid tumours larger than 15 mm. Eur Radiol. 2011;21:1865–73.PubMedCrossRef
8.
go back to reference Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745–9.PubMedCrossRef Cavalier E, Daly AF, Betea D, et al. The ratio of parathyroid hormone as measured by third- and second-generation assays as a marker for parathyroid carcinoma. J Clin Endocrinol Metab. 2010;95:3745–9.PubMedCrossRef
9.
go back to reference Caron P, Maiza JC, Renaud C, et al. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70:533–8.CrossRef Caron P, Maiza JC, Renaud C, et al. High third generation/second generation PTH ratio in a patient with parathyroid carcinoma: clinical utility of third generation/second generation PTH ratio in patients with primary hyperparathyroidism. Clin Endocrinol (Oxf). 2009;70:533–8.CrossRef
10.
go back to reference Rubin MR, Silverberg SJ, D’Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.PubMedCrossRef Rubin MR, Silverberg SJ, D’Amour P, et al. An N-terminal molecular form of parathyroid hormone (PTH) distinct from hPTH(1 84) is overproduced in parathyroid carcinoma. Clin Chem. 2007;53:1470–6.PubMedCrossRef
12.
go back to reference Schulte KM, Gill A, Barczinski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–8.PubMedCrossRef Schulte KM, Gill A, Barczinski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–8.PubMedCrossRef
13.
go back to reference Schulte KM, Talat N, Miell J, et al. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010;34:2611–20.PubMedCrossRef Schulte KM, Talat N, Miell J, et al. Lymph node involvement and surgical approach in parathyroid cancer. World J Surg. 2010;34:2611–20.PubMedCrossRef
14.
go back to reference DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: International Agency for Research on Cancer; 2004. DeLellis RA, Lloyd RV, Heitz PU, Eng C. Pathology and genetics of tumours of endocrine organs (WHO classification). Lyon: International Agency for Research on Cancer; 2004.
15.
go back to reference Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.PubMedCrossRef Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.PubMedCrossRef
17.
go back to reference Montenegro FL, Tavares MR, Durazzo MD, et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J. 2006;124:42–4.PubMedCrossRef Montenegro FL, Tavares MR, Durazzo MD, et al. Clinical suspicion and parathyroid carcinoma management. Sao Paulo Med J. 2006;124:42–4.PubMedCrossRef
18.
go back to reference Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.PubMedCrossRef Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.PubMedCrossRef
19.
go back to reference Robbins KT. Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin North Am. 1998;31:639–55.PubMedCrossRef Robbins KT. Classification of neck dissection: current concepts and future considerations. Otolaryngol Clin North Am. 1998;31:639–55.PubMedCrossRef
20.
go back to reference Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg. 1985;149:522–7.PubMedCrossRef Wang CA, Gaz RD. Natural history of parathyroid carcinoma. Diagnosis, treatment, and results. Am J Surg. 1985;149:522–7.PubMedCrossRef
21.
go back to reference Iihara M, Okamoto T, Suzuki R, et al. Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery. 2007;142:936–43; discussion 943e1.PubMedCrossRef Iihara M, Okamoto T, Suzuki R, et al. Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis. Surgery. 2007;142:936–43; discussion 943e1.PubMedCrossRef
22.
go back to reference Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85.PubMedCrossRef Kebebew E, Arici C, Duh QY, Clark OH. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–85.PubMedCrossRef
23.
24.
go back to reference Ippolito G, Palazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–70.PubMedCrossRef Ippolito G, Palazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–70.PubMedCrossRef
25.
go back to reference Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255–64.PubMedCrossRef Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis? Cancer. 2007;110:255–64.PubMedCrossRef
26.
go back to reference Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98:2378–84.PubMedCrossRef Munson ND, Foote RL, Northcutt RC, et al. Parathyroid carcinoma: is there a role for adjuvant radiation therapy? Cancer. 2003;98:2378–84.PubMedCrossRef
Metadata
Title
Oncologic Resection Achieving R0 Margins Improves Disease-Free Survival in Parathyroid Cancer
Authors
K. M. Schulte, MD, FRCS
N. Talat, BSc (Hons)
G. Galata, MD
J. Gilbert, PhD
J. Miell, FRCPE, FRCP
L. C. Hofbauer, MD
A. Barthel, MD
S. Diaz-Cano, MD, PhD, FRCPath
S. R. Bornstein, MD, PhD
Publication date
01-06-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 6/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3530-z

Other articles of this Issue 6/2014

Annals of Surgical Oncology 6/2014 Go to the issue